{
    "thread": {
        "uuid": "2fb4291fcff662a42639473a97ac722a79d83742",
        "url": "https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-24/doc-ineufhci3232175.shtml",
        "site_full": "finance.sina.com.cn",
        "site": "sina.com.cn",
        "site_section": "https://finance.sina.cn",
        "site_categories": [
            "tech",
            "top_news_hk",
            "top_news_sg",
            "top_news_tw",
            "top_news"
        ],
        "section_title": "新浪财经_金融信息服务商",
        "site_title": null,
        "title": "亚盛医药-B(06855)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告|美国_新浪财经_新浪网",
        "title_full": "亚盛医药-B(06855)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告|美国_新浪财经_新浪网",
        "published": "2025-04-24T02:18:00.000+03:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "CN",
        "main_image": "",
        "performance_score": 0,
        "domain_rank": 254,
        "domain_rank_updated": "2025-04-22T00:00:00.000+03:00",
        "licensing_agency": [],
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "2fb4291fcff662a42639473a97ac722a79d83742",
    "url": "https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-24/doc-ineufhci3232175.shtml",
    "ord_in_thread": 0,
    "author": "sina.com.cn",
    "published": "2025-04-24T02:18:00.000+03:00",
    "title": "亚盛医药-B(06855)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告|美国_新浪财经_新浪网",
    "text": "亚盛医药-B (06855)发布公告，公司细胞凋亡管线重点品种Bcl-2选择性抑制剂Lisaftoclax(APG-2575)和MDM2-p53抑制剂Alrizomadlin (APG-115)的两项临床研究成果入选2025年美国临床肿瘤学会(ASCO)年会，其中，APG-2575联合治疗髓系恶性肿瘤患者的Ib/II期研究最新进展获口头报告。\n一年一度的ASCO年会是全球肿瘤领域最重要、最权威的学术交流盛会，将展示当前国际最前沿的临床肿瘤学科研成果和肿瘤治疗技术。本届ASCO年会将于2025年5月30日至2025年6月3日(美国当地时间)在芝加哥McCormick会议中心以线上线下结合的形式举办。\n亚盛医药将在本届ASCO年会展示的临床研究进展包括：\n一项评估APG-2575(Lisaftoclax)联合阿扎胞苷(AZA)治疗初治(TN)或既往接受过维奈克拉(VEN)治疗的髓系恶性肿瘤患者(Pts)的Ib/II期临床研究\n一项评估新型MDM2抑制剂APG-115(Alrizomadlin)单药或联合特瑞普利单抗治疗晚期腺样囊性癌(ACC)或其它实体瘤患者(Pts)的II期临床研究",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "chinese",
    "sentiment": "positive",
    "categories": [
        "Health"
    ],
    "topics": [
        "Health->cancer",
        "Health->health treatment and procedure"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": true,
    "webz_reporter": false,
    "external_links": [],
    "entities": {
        "persons": [],
        "locations": [],
        "organizations": []
    },
    "syndication": {
        "syndicated": null,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "trust": {
        "categories": [],
        "bias": null,
        "source": {
            "type": null,
            "city": null,
            "state": null,
            "country": null,
            "domain_type": null,
            "agency": null,
            "organization_name": null
        }
    },
    "rating": null,
    "crawled": "2025-04-24T02:23:25.710+03:00",
    "updated": "2025-04-24T02:23:25.710+03:00"
}